希罗达联合唑来膦酸治疗乳腺癌多发骨转移疗效观察  

Therapeutic effect of xeloda combined with zoledronic acid on breast cancer with multiple bone metastases

作　　者：车建华[1] 杨保庆[1] 杨玲玲[1] 潘海波[1] 

机构地区：[1]广西壮族自治区钦州市第一人民医院放疗科,535000

出　　处：《实用医学杂志》2012年第6期979-981,共3页The Journal of Practical Medicine

摘　　要：目的:观察评价希罗达(卡培他滨)联合唑来膦酸治疗乳腺癌多发骨转移的效果及安全性。方法:采用随机对照研究,56例乳腺癌多发骨转移分为治疗组与对照组,治疗组28例给予希罗达片口服化疗联合唑来膦酸治疗。对照组28例单纯给予希罗达治疗。对两组进行治疗并比较和分析治疗结果。结果:两组治疗的有效率、临床获益率分别为57.1%、75.0%和46.4%、60.7%;两组近期疗效、生存质量改善及毒副反应比较,无统计学差异(P>0.05)。治疗组骨痛缓解率及骨转移灶修率分别是82.1%和75.0%,高于对照组(42.8%和46.4%),差异有统计学意义(P<0.05)。结论:希罗达联合唑来膦酸治疗乳腺癌多发骨转移具有协同效应,较单用希罗达近期疗效好,骨痛缓解、骨转移灶修复明显。Objective To investigate the efficacy and safety of xeloda combined with zoledronic acid in the treatment for breast cancer with multiple bone metastases. Methods Fifty-six patients with breast cancer combined with multiple bone metastases were randomly assigned to trial group （n = 28） and control group （n = 28）. Patients in trial group was administered with xeloda plus zoledronic acid and patients in control group was administered with xeloda alone. The efficacy of the two groups was analyzed and compared. Results The overall response and the clinical benefit rates of the trial group were 57.1% and 75.0%, and those of the control group were 46.4% and 60.7%. The curative efficacy, improvement in quality of life, and toxic side effects between the two groups showed no significant difference （P 〉 0.05）. Relief rate of bone pain and the effect on bone metastases were 82.1% and 75% in trial group, which were significantly higher than those in control group （42.8% and 46.4%）（P 〈 0.05）. Conclusions Xeloda combined with zoledronic acid in the treatment for breast cancer with bone metastases has synergistic and favorable therapeutic effects on bone metastases and relief of bone pain.

关 键 词：乳腺肿瘤 卡培他滨 唑来膦酸 

分 类 号：R737.9[医药卫生—肿瘤]